Skip to main content

Advertisement

SpringerLink
Log in

Approaches to Oligometastatic Renal Cell Carcinoma

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

This study aims to gather the current state of the literature about therapeutic approaches and management of oligometastatic renal cell carcinoma.

Recent Findings

Two recent stereotactic body radiotherapy (SBRT) studies gained attention and offered a promising outcome alone or in association with antineoplastic drugs especially in oligometastatic renal cell carcinoma.

Summary

If one can consider evidence-based medicine as the sole therapeutic option, many unresolved questions are still pending. Thus, therapeutic approaches in oligometastatic renal cell carcinoma are still working. Further phase III clinical trials are urgently needed to validate the last 2 phase II involving SBRT and improve knowledge for defining the right care to the right patient at the right time. In addition, a discussion in a disciplinary consultation meeting remains essential to validate the arrangement between systemic treatments and focal treatments that will best benefit the patient.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10. https://doi.org/10.1200/JCO.1995.13.1.8. This editorial was the first to describe the concept of an oligometastatic disease.

    Article  CAS  PubMed  Google Scholar 

  2. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82. https://doi.org/10.1038/nrclinonc.2011.44. This review supported that oligometastasis is a distinct clinical entity through clinical and laboratory data.

    Article  CAS  PubMed  Google Scholar 

  3. Gutiontov SI, Pitroda SP, Tran PT, Weichselbaum RR. (Oligo)metastasis as a spectrum of disease. Cancer Res. 2021;81(10):2577–83. https://doi.org/10.1158/0008-5472.CAN-20-3337.

    Article  CAS  PubMed  Google Scholar 

  4. Kissel M, Helou J, Thariat J. Definitions of oligometastatic disease and new treatment concepts. Bull Cancer. 2018;105(7–8):696–706. https://doi.org/10.1016/j.bulcan.2018.04.012.

    Article  PubMed  Google Scholar 

  5. Rolley C, Aubert C, Baize N, Bigot P. Management of metastatic renal cell carcinomass. Prog Urol. 2018;28(14):777–82. https://doi.org/10.1016/j.purol.2018.07.280.

    Article  CAS  PubMed  Google Scholar 

  6. Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA. Management of metastatic clear cell renal cell carcinoma: ASCO Guideline. J Clin Oncol. 2022;40(25):2957–95. https://doi.org/10.1200/JCO.22.00868.

    Article  CAS  PubMed  Google Scholar 

  7. Lehrer EJ, Stoltzfus KC, Jones BM, Gusani NJ, Walter V, Wang M, Trifiletti DM, Siva S, Louie AV, Zaorsky NG. Trends in diagnosis and treatment of metastatic cancer in the United States. Am J Clin Oncol. 2021;44(11):572–9. https://doi.org/10.1097/COC.0000000000000866.

    Article  CAS  PubMed  Google Scholar 

  8. Méjean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L, Lang H, Guy L, Gravis G, Rolland F, Linassier C, Lechevallier E, Beisland C, Aitchison M, Oudard S, Patard JJ, Theodore C, Chevreau C, Laguerre B, Hubert J, Gross-Goupil M, Bernhard JC, Albiges L, Timsit MO, Lebret T, Escudier B. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med. 2018;379(5):417–27. https://doi.org/10.1056/NEJMoa1803675.

    Article  PubMed  Google Scholar 

  9. De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, Briganti A, Fonteyne V, Van Vulpen M, Lumen N, Spahn M, Mareel M. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15(4):e170–7. https://doi.org/10.1016/S1470-2045(13)70569-2.

    Article  PubMed  Google Scholar 

  10. Vallard A, Vial N, Jmour O, Rehailia-Blanchard A, Trone JC, Sotton S, Daguenet E, Guy JB, Magne N. Stereotactic body radiotherapy: passing fad or revolution? Bull Cancer. 2020;107(2):244–53. https://doi.org/10.1016/j.bulcan.2019.09.011.

    Article  PubMed  Google Scholar 

  11. Vial N, Nevesny S, Sotton S, Moslemi D, Jmour O, Guillaume E, Rehailia-Blanchard A, Trone JC, Langrand-Escure J, Vallard A, Magne N. Focus on the expected quality of reporting in SBRT/radiosurgery prospective studies: how far have we come in 30 years? Br J Radiol. 2021;94(1121):20200115. https://doi.org/10.1259/bjr.20200115.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Bedke J, Albiges L, Capitanio U, Giles RH, Hora M, Lam TB, Ljungberg B, Marconi L, Klatte T, Volpe A, Abu-Ghanem Y, Dabestani S, Pello SF, Hofmann F, Kuusk T, Tahbaz R, Powles T, Bex A. The 2021 updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibitor-based combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma are standard of care. Eur Urol. 2021;80(4):393–7. https://doi.org/10.1016/j.eururo.2021.04.042.

    Article  PubMed  Google Scholar 

  13. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T, KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. https://doi.org/10.1056/NEJMoa1816714.

    Article  CAS  PubMed  Google Scholar 

  14. Gurram S, Al Harthy M, Ball MW. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update. Discov Med. 2020;29(158):191–9.

    PubMed  Google Scholar 

  15. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EE, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118(11):2962–70. https://doi.org/10.1002/cncr.26611.

    Article  PubMed  Google Scholar 

  16. Stenman M, Sinclair G, Paavola P, Wersäll P, Harmenberg U, Lindskog M. Overall survival after stereotactic radiotherapy or surgical metastasectomy in oligometastatic renal cell carcinoma patients treated at two Swedish centres 2005–2014. Radiother Oncol. 2018;127(3):501–6. https://doi.org/10.1016/j.radonc.2018.04.028.

    Article  CAS  PubMed  Google Scholar 

  17. Maciolek KA, Abel EJ, Best SL, Emamekhoo H, Averill SL, Ziemlewicz TJ, Lubner MG, Hinshaw JL, Lee FT Jr, Wells SA. Percutaneous microwave ablation for local control of metastatic renal cell carcinoma. Abdom Radiol (NY). 2018;43(9):2446–54. https://doi.org/10.1007/s00261-018-1498-z.

    Article  PubMed  Google Scholar 

  18. Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan S, Ponsky L, Ellis R, Kaplan I, Mahadevan A, Chu W, Swaminath A, Onishi H, Teh B, Correa RJ, Lo SS, Staehler M. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 2018;124(5):934–42. https://doi.org/10.1002/cncr.31156.

    Article  PubMed  Google Scholar 

  19. Guckenberger M. Stereotactic body radiotherapy as “first-line treatment” for oligometastatic renal cell cancer. Strahlenther Onkol. 2022;198(5):497–9. https://doi.org/10.1007/s00066-022-01920-7.

    Article  PubMed  Google Scholar 

  20. Zaorsky NG, Lehrer EJ, Kothari G, Louie AV, Siva S. Stereotactic ablative radiation therapy for oligometastatic renal cell carcinoma (SABR ORCA): a meta-analysis of 28 studies. Eur Urol Oncol. 2019;2(5):515–23. https://doi.org/10.1016/j.euo.2019.05.007.

    Article  PubMed  Google Scholar 

  21. Sogono P, Bressel M, David S, Shaw M, Chander S, Chu J, Plumridge N, Byrne K, Hardcastle N, Kron T, Wheeler G, Hanna GG, MacManus M, Ball D, Siva S. Safety, efficacy, and patterns of failure after single-fraction stereotactic body radiation therapy (SBRT) for oligometastases. Int J Radiat Oncol Biol Phys. 2021;109(3):756–63. https://doi.org/10.1016/j.ijrobp.2020.10.011.

    Article  PubMed  Google Scholar 

  22. Tang C, Msaouel P, Hara K, Choi H, Le V, Shah AY, Wang J, Jonasch E, Choi S, Nguyen QN, Das P, Prajapati S, Yu Z, Khan K, Powell S, Murthy R, Sircar K, Tannir NM. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. Lancet Oncol. 2021;22(12):1732–9. https://doi.org/10.1016/S1470-2045(21)00528-3. This study is the first prospective trial of serial definitive local therapy as a single modality to treat oligometastatic renal cell carcinoma.

    Article  PubMed  Google Scholar 

  23. Siva S, Bressel M, Wood ST, Shaw MG, Loi S, Sandhu SK, Tran B, Azad AA, Lewin JH, Cuff KE, Liu HY, Moon D, Goad J, Wong LM, LimJoon M, Mooi J, Chander S, Murphy DG, Lawrentschuk N, Pryor D. Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial. Eur Urol. 2022;81(4):364–72. https://doi.org/10.1016/j.eururo.2021.12.006. RAPPORT trial is the first study to prospectively evaluate stereotactic ablative body radiotherapy (and immunotherapy in patients with oligometastatic clear cell renal cell carcinoma).

    Article  CAS  PubMed  Google Scholar 

  24. Le Guevelou J, Sargos P, Siva S, Ploussard G, Ost P, Gillessen S, Zilli T. The emerging role of extracranial stereotactic ablative radiotherapy for metastatic renal cell carcinoma: a systematic review. Eur Urol Focus. 2023;9:114–24. This recent review summarizes the current and future roles of stereotactic ablative body radiotherapy in patients with metastatic renal cell carcinoma, with both synchronous and metachronous extracranial metastases.

  25. Magné N, Latorzeff I. Oligometastatic renal cell carcinoma: radiotherapy as a new standard of care ? Lancet Oncol. 2021;22(12):1644–5. https://doi.org/10.1016/S1470-2045(21)00665-3.

    Article  PubMed  Google Scholar 

  26. Siva S, Louie AV. Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma - buying time or time to change? Nat Rev Urol. 2022;19(4):197–8. https://doi.org/10.1038/s41585-021-00560-3.

    Article  PubMed  Google Scholar 

  27. Marvaso G, Corrao G, Oneta O, Pepa M, Zaffaroni M, Corso F, Gandini S, Cecconi A, Zerini D, Mazzola GC, Augugliaro M, Cossu Rocca M, Verri E, Cattani F, La Fauci F, Bergamaschi L, Luzzago S, Mistretta AF, Musi G, Nolè F, De Cobelli O, Orecchia R, Jereczek-Fossa BA. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how? Clin Transl Oncol. 2021;23(8):1717–26. https://doi.org/10.1007/s12094-021-02574-0.

    Article  CAS  PubMed  Google Scholar 

  28. Langrand-Escure J, Vallard A, Rivoirard R, Méry B, Guy JB, Espenel S, Trone JC, Ben Mrad M, Diao P, Rancoule C, Suchaud JP, Fournel P, Guillot A, Chargari C, Escudier B, Négrier S, Magné N. Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma: a real-life report. Anticancer Drugs. 2016;27(5):427–32. https://doi.org/10.1097/CAD.0000000000000349.

    Article  CAS  PubMed  Google Scholar 

  29. Kroeze SGC, Fritz C, Schaule J, Siva S, Kahl KH, Sundahl N, Blanck O, Kaul D, Adebahr S, Verhoeff JJC, Skazikis G, Roeder F, Geier M, Eckert F, Guckenberger M. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. BJU Int. 2021;127(6):703–11. https://doi.org/10.1111/bju.15284.

    Article  CAS  PubMed  Google Scholar 

  30. Martin-Romano P, Adam J, Scoazec JY, Gouy S, Levy A, Baldini C, Champiat S, Soria JC, Massard C, Marabelle A, Deutsch E, Hollebecque A. Case report: response to immunotherapy, can radiotherapy be a troublemaker? Front Immunol. 2021;12:745146. https://doi.org/10.3389/fimmu.2021.745146.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Daguenet E, Khalifa J, Tolédano A, Borchiellini D, Pointreau Y, Rodriguez-Lafrasse C, Chargari C, Magné N. To exploit the 5 ‘R’ of radiobiology and unleash the 3 ‘E’ of immunoediting: ‘RE’-inventing the radiotherapy-immunotherapy combination. Ther Adv Med Oncol. 2020;12:1758835920913445. https://doi.org/10.1177/1758835920913445.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, Dingemans AC, Fournier B, Hurkmans C, Lecouvet FE, Meattini I, Méndez Romero A, Ricardi U, Russell NS, Schanne DH, Scorsetti M, Tombal B, Verellen D, Verfaillie C, Ost P. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–28. https://doi.org/10.1016/S1470-2045(19)30718-1.

    Article  PubMed  Google Scholar 

  33. Zilli T, Achard V, Dal Pra A, Schmidt Hegemann N, AlicjaJereczek-Fossa B, Lancia A, Ingrosso G, Alongi F, Aluwini S, Arcangeli S, Blanchard P, Conde Moreno A, Couñago F, Créhange G, Dirix P, Gomez Iturriaga A, Guckenberger M, Pasquier D, Sargos P, Scorsetti M, Supiot S, Tree AC, Zapatero A, Le Guevelou J, Ost P, Belka C. Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus. Radiother Oncol. 2022;176:199–207. https://doi.org/10.1016/j.radonc.2022.10.005.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Institut Bergonié, 229 cours de l’Argonne, 33000, Bordeaux, France

    Nicolas Magne, Nicolas Milhade & Paul Sargos

  2. Cellular and Molecular Radiobiology Laboratory, Lyon-Sud Medical School, Unité Mixte de Recherche CNRS5822/IP2I, University of Lyon, Lyon, France

    Nicolas Magne

  3. Department of Medical Oncology, North Hospital, University Hospital of Saint-Etienne, Saint-Etienne, France

    Wafa Bouleftour

Authors
  1. Nicolas Magne
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicolas Milhade
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paul Sargos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wafa Bouleftour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicolas Magne.

Ethics declarations

Conflict of Interest

The authors declare no competing interests.

Human and Animal Rights and Informed Consent

Non applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Magne, N., Milhade, N., Sargos, P. et al. Approaches to Oligometastatic Renal Cell Carcinoma. Curr Oncol Rep 25, 251–256 (2023). https://doi.org/10.1007/s11912-023-01379-4

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-023-01379-4

Keywords

Search

Navigation